Perlecan-targeted nanoparticles for drug delivery to triple-negative breast cancer.

We previously developed two antibodies that bind to a cell surface protein, perlecan, overexpressed in triple-negative breast cancer (TNBC). The goal of this study was to investigate these antibodies as targeting ligands for nanoparticle-mediated drug delivery. Paclitaxel-loaded poly(D,L-lactide-co-glycolide) nanoparticles were functionalized with antibodies using thiol-maleimide chemistry. Effect of antibody functionalization on therapeutic efficacy of drug-loaded nanoparticles was investigated using The antibodies were covalently conjugated to nanoparticles without affecting antibody binding affinity or nanoparticle properties. Perlecan-targeted nanoparticles showed improved cell uptake, retention, cytotoxicity The data presented here indicates that perlecan-targeted nanoparticles can improve tumor drug delivery to TNBC.

Déclaration de conflit d'intérêts

Financial & competing interests disclosure J Panyam, V Khanna and S Kalscheuer have a US patent application disclosing the composition of the antibody reagents and their use described in this manuscript. Funding was provided by the Community of Pharmaceutical Development (to J Panyam) and NIH EB 019893 (to J Panyam). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilized in the production of this manuscript.